Market Overview

UPDATE: Deutsche Bank Ups PT to $45 on Medtronic on Top-Line Beat

Share:
Related MDT
Benzinga's Top Upgrades
Medtronic To Acquire RF Surgical Systems
10 Top Healthcare Dividend Dogs: 11% To 47.9% Upsides And 12.1% To 48.3% Net Gains As Of July 29 (Seeking Alpha)

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) and raised its price target from $43 to $45.

Deutsche Bank noted, "In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42,65 on Tuesday.

Latest Ratings for MDT

DateFirmActionFromTo
Jul 2015BTIG ResearchUpgradesNeutralBuy
Mar 2015BMO CapitalMaintainsOutperform
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MDT)

Get Benzinga's Newsletters